“Comparative Efficacy of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Treatment Response in Atopic Dermatitis at Varying Treatment Continuance Rates” (2025) SKIN The Journal of Cutaneous Medicine, 9(1), p. s519. doi:10.25251/skin.9.supp.519.